دورية أكاديمية
Factors associated with the clinical outcome of patients with relapsed/refractory CD19+acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy
| العنوان: | Factors associated with the clinical outcome of patients with relapsed/refractory CD19+acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy |
|---|---|
| المؤلفون: | Ortiz-Maldonado Gibson, Valentín, Rives, Susana, Español Rego, Marta, Alonso Saladrigues, A., Montoro, Mercedes, Magnano, Laura, Giné Soca, Eva, Pascal i Capdevila, Mariona, Díaz Beyà, Marina, Castella, Maria, Català, Albert, Faura, Anna, Rodríguez Lobato, Luis Gerardo, Oliver Caldés, Aina, Martínez Roca, Alexandra, Rovira, Montserrat, González Navarro, Europa Azucena, Ortega, Juan Ramón, Cid Vidal, Joan, Lozano, Miquel, García Rey, Enric, Fernández, Sara, Castro Rebollo, Pedro, Jordán García, Iolanda, Villamor i Casas, Neus, Aymerich Gregorio, Marta, Torrebadell Burriel, Montserrat, Deyá, Angela, Fernández de Larrea Rodríguez, Carlos José, Benítez-Ribas, Daniel, Trias, Esteve, Varea, Sara, Calvo Rojas, Gonzalo, Esteve, Jordi, Urbano Ispizua, Álvaro, Juan, Manel, Delgado, Julio (Delgado González) |
| المصدر: | Articles publicats en revistes (Medicina) |
| بيانات النشر: | BMJ Publishing Group |
| سنة النشر: | 2021 |
| المجموعة: | Dipòsit Digital de la Universitat de Barcelona |
| مصطلحات موضوعية: | Leucèmia limfocítica crònica, Cèl·lules canceroses, Teràpia cel·lular, Antígens CD, Immunoteràpia, Receptors cel·lulars, Chronic lymphocytic leukemia, Cancer cells, Cellular therapy, CD antigens, Immunotheraphy, Cell receptors |
| الوصف: | The prognosis of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains poor, particularly for those relapsing after allogeneic hema-topoietic cell transplantation (alloHCT). Novel agents such as inotuzumab ozogamicin or blinatumomab achieve increased response rates, but these are generally transient unless followed by alloHCT. Chimeric antigen receptors (CAR) targeting CD19 have shown promising results in R/R ALL, and one of these products (tisagenlecleucel) has been approved for the treatment of patients with R/R ALL up to 25 years of age. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | 4 p.; application/pdf |
| اللغة: | English |
| تدمد: | 2051-1426 |
| العلاقة: | Reproducció del document publicat a: https://doi.org/10.1136/jitc-2021-003644Test; Journal for ImmunoTherapy of Cancer , 2021, vol. 9, num. 12, p. e003644; https://doi.org/10.1136/jitc-2021-003644Test; http://hdl.handle.net/2445/193208Test; 718809 |
| الإتاحة: | https://doi.org/10.1136/jitc-2021-003644Test http://hdl.handle.net/2445/193208Test |
| حقوق: | cc-by-nc (c) Ortiz-Maldonado, Valentín et al., 2021 ; https://creativecommons.org/licenses/by-nc/4.0Test/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.ECA94504 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 20511426 |
|---|